MTOR and colorectal cancer: We chose a well-characterized human colorectal cancer cell line, HCT116, and tested serial dilutions of Zeocin vs either AZD8055, an mTOR catalytic inhibitor52, cytochalasin D, which inhibits actin polymerization, or nocodazole, each used at sublethal concentrations53.